AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $327.36 million. The enterprise value is $217.81 million.
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 99.20 million shares outstanding. The number of shares has increased by 1.06% in one year.
| Current Share Class | 99.20M |
| Shares Outstanding | 99.20M |
| Shares Change (YoY) | +1.06% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 4.24% |
| Owned by Institutions (%) | 6.18% |
| Float | 38.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 72.65 |
| Forward PS | 8.90 |
| PB Ratio | 5.93 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.02 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -360.54 |
Financial Efficiency
Return on equity (ROE) is -89.65% and return on invested capital (ROIC) is -51.51%.
| Return on Equity (ROE) | -89.65% |
| Return on Assets (ROA) | -22.35% |
| Return on Invested Capital (ROIC) | -51.51% |
| Return on Capital Employed (ROCE) | -115.62% |
| Weighted Average Cost of Capital (WACC) | 13.04% |
| Revenue Per Employee | $36,934 |
| Profits Per Employee | -$728,210 |
| Employee Count | 122 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +111.54% in the last 52 weeks. The beta is 1.63, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | +111.54% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 2.83 |
| Relative Strength Index (RSI) | 60.32 |
| Average Volume (20 Days) | 251,819 |
Short Selling Information
The latest short interest is 2.96 million, so 6.33% of the outstanding shares have been sold short.
| Short Interest | 2.96M |
| Short Previous Month | 3.09M |
| Short % of Shares Out | 6.33% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.93 |
Income Statement
In the last 12 months, AC Immune had revenue of $4.51 million and -$88.84 million in losses. Loss per share was -$0.88.
| Revenue | 4.51M |
| Gross Profit | -66.67M |
| Operating Income | -86.84M |
| Pretax Income | -88.84M |
| Net Income | -88.84M |
| EBITDA | -85.09M |
| EBIT | -86.84M |
| Loss Per Share | -$0.88 |
Full Income StatementBalance Sheet
The company has $115.28 million in cash and $5.73 million in debt, with a net cash position of $109.55 million or $1.10 per share.
| Cash & Cash Equivalents | 115.28M |
| Total Debt | 5.73M |
| Net Cash | 109.55M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 56.60M |
| Book Value Per Share | 0.56 |
| Working Capital | 2.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.35 million and capital expenditures -$1.14 million, giving a free cash flow of -$89.58 million.
| Operating Cash Flow | -87.35M |
| Capital Expenditures | -1.14M |
| Depreciation & Amortization | 1.78M |
| Net Borrowing | -1.31M |
| Free Cash Flow | -89.58M |
| FCF Per Share | -$0.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,927.32% |
| Pretax Margin | -1,971.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.06% |
| Shareholder Yield | -1.06% |
| Earnings Yield | -27.14% |
| FCF Yield | -27.36% |
Analyst Forecast
The average price target for AC Immune is $10.00, which is 203.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 203.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 108.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -4.33 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.33 |
| Piotroski F-Score | 1 |
